| 1252607-60-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• CAS: 1252607-60-5
• 化学式: C₁₅H₁₆O₄
• 分子量: 260.29
• InChiKey: IYXBLLLQIXHQHI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  在 盐酸 水 、 丙酮 作用下， 反应 4.0h， 生成 3H,4'H-spiro[2-benzofuran-1,1'-cyclohexane]-3,4'-dione
  参考文献：
  名称：

  N-substituted piperidines and their use as pharrmaceuticals

  摘要：

  本发明涉及11-β羟基类固醇脱氢酶类型1的抑制剂、矿物皮质激素受体（MR）的拮抗剂以及其药物组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶类型1的表达或活性有关的各种疾病，以及与醛固酮过量有关的疾病。

  公开号：

  US20060004049A1
• 作为产物：
  描述：

  1,4-环己二酮单乙二醇缩酮 、 2-溴苯甲酸 在 正丁基锂 、 二丁基镁 、 盐酸 作用下， 以 四氢呋喃 、 正己烷 、 正庚烷 、 水 为溶剂， 反应 2.33h， 生成
  参考文献：
  名称：

  N-substituted piperidines and their use as pharrmaceuticals

  摘要：

  本发明涉及11-β羟基类固醇脱氢酶类型1的抑制剂、矿物皮质激素受体（MR）的拮抗剂以及其药物组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶类型1的表达或活性有关的各种疾病，以及与醛固酮过量有关的疾病。

  公开号：

  US20060004049A1

文献信息

• 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2
  申请人：Zhang Xuqing

  公开号：US20100267668A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I). wherein: X, R 1 , R 2 , R 3 , and R 4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括式(I)的化合物。其中：X、R1、R2、R3和R4如规范中所定义。该发明还包括一种预防、治疗或改善综合症、紊乱或疾病的方法，其中所述综合症、紊乱或疾病是II型糖尿病、肥胖和哮喘。该发明还包括通过给哺乳动物施用至少一种式(I)化合物的治疗有效量来抑制CCR2活性的方法。
• Synthesis and evaluation of a spiro-isobenzofuranone class of histamine H3 receptor inverse agonists
  作者：Makoto Jitsuoka、Daisuke Tsukahara、Sayaka Ito、Takeshi Tanaka、Norihiro Takenaga、Shigeru Tokita、Nagaaki Sato

  DOI：10.1016/j.bmcl.2008.07.125

  日期：2008.9

  Spiro-isobenzofuranones 1a and 1b were discovered as potent, selective, and brain-penetrable non-imidazole H-3 receptor inverse agonists. Our corporate sample collection was screened to identify 2a as a lead. Recognizing the right-hand portion of 2a as an essential pharmacophore, an extensive screen of the left-hand piperidine portion was carried out to yield the potent spiro-derivatives 2t-x. Spiro-isobenzofuranone 2x, the most potent among the derivatives, was converted to the corresponding amide 1a, which possessed dramatically improved H3 activity (IC50 = 0.72 nM; more than 20-fold improvement over 2x). Further elaboration led to the identification of 1b, a 5-methoxy derivative with an IC50 of 0.54 nM. Our studies demonstrated that derivatives 1a and 1b to be potent, selective, and brain-penetrable H-3 inverse agonists. (C) 2008 Elsevier Ltd. All rights reserved.
• Identification of positron emission tomography ligands for NPY Y5 receptors in the brain
  作者：Hirobumi Takahashi、Yuji Haga、Takunobu Shibata、Katsumasa Nonoshita、Toshihiro Sakamoto、Minoru Moriya、Tomoyuki Ohe、Masato Chiba、Yuko Mitobe、Hidefumi Kitazawa、Hisashi Iwaasa、Akane Ishihara、Yasuyuki Ishii、Akio Kanatani、Takehiro Fukami

  DOI：10.1016/j.bmcl.2009.07.103

  日期：2009.9

  A series of trans-3-oxospiro[(aza)isobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide derivatives were synthesized and profiled for NPY Y5 binding affinity, brain and CSF penetrability in rats, and susceptibility to human and mouse P-glycoprotein transporters in order to develop a PET ligand. Compound 12b exhibited an acceptable profile for a PET ligand, and [C-11]12b was successfully utilized in clinical settings as a Y5 PET ligand. (C) 2009 Elsevier Ltd. All rights reserved.
• US8324186B2
  申请人：——

  公开号：US8324186B2

  公开（公告）日：2012-12-04
• [EN] 4-AZETIDINYL-1-HETEROATOM LINKED-CYCLOHEXANE ANTAGONISTS OF CCR2<br/>[FR] ANTAGONISTES DE CCR2 À BASE DE 4-AZÉTIDINYL-1-HÉTÉROATOME-CYCLOHEXANE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010121036A1

  公开（公告）日：2010-10-21

  The present invention comprises compounds of Formula (I). wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).